Synapse
⌘+K
Synapse
PulseExploreClubsResearchersJournals
Instagram
HomeClubsExplore
December 8, 2025BloodOpen Access

Post-transplant cyclophosphamide-based graft-verses-host disease (GVHD) prophylaxis is associated with a low incidence of fibrotic chronic GVHD after allogeneic hematopoietic cell transplantation across diverse donor types

View Full Paper
Ask AI
Bookmark
Share

Authors

KKK.H. KimJTJose TinajeroKSKaramjeet S. Sandhu

Discussion

Loading...

Member takes

Overview

Retrospective study shows post-transplant cyclophosphamide lowers chronic GVHD incidence in transplant recipients, indicating its effectiveness.

Key Points

  • To assess the impact of post-transplant cyclophosphamide on chronic graft-versus-host disease (GVHD) after allogeneic stem cell transplantation.
  • Retrospective cohort study of 462 adult patients undergoing alloHCT with PTCy as GVHD prophylaxis.
  • Exclusions included patients receiving concurrent therapies and those with prior relapses or second HCT.
  • Primary endpoints were incidence and severity of cGVHD, particularly fibrotic features, using the NIH consensus criteria.
  • 43% of patients developed cGVHD, with fibrotic manifestations being infrequent.
  • Two-year cumulative cGVHD incidence was 46% for haplo donors, 40% for mMUD and MUD.
  • Most patients with moderate-to-severe cGVHD responded to first-line corticosteroids or ruxolitinib therapy.

Cite This Study

Kim et al. (2025) studied this question.

synapsesocial.com/papers/69362f5d4fa91c937236dc9dhttps://doi.org/10.1182/blood-2025-935
View Full Paper
Ask AI
Bookmark
Share